Current and Emerging Therapies Have No Advantage Over Enbrel in Reducing the Signs and Symptoms of Rheumatoid Arthritis
Golimumab Will Earn Decision Resources' Gold Standard for Rheumatoid Arthritis in 2012, According to a New Report from Decision Resources
WALTHAM, Mass., Jan. 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues...
FDA Panel Recommends Enbrel for Pediatric Patients
But experts also express concern about psoriasis drug's possible risks for children; action follows agency warning that drug label needs strengthening
WEDNESDAY, June 18 (HealthDay News) -- A U.S. Food and Drug Administration advisory panel recommended Wednesday that the psoriasis dru...
New findings show Enbrel significantly reduced levels of C-reactive protein
SAN ANTONIO, Texas, (Feb. 1, 2008) - Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced findings from a retrospective analysis, which demonstrated that ENBREL
reduced C-reactive protein (CRP), a marker of inflammation, in patients with moderate to seve...
Combination Therapy With ENBREL And Methotrexate Found Effective In RA Treatment
Combination therapy with anti-TNF agents (etanercept) and chemotherapy drug methotrexate has been shown to be effective in the treatment of Rheumatoid Arthritis.// Furthermore, the progression of joint damage has been considerably slowed down in over three quarters of patients. The chronic nature o...
Decision Resources' Updated Rheumatoid Arthritis Report Now Includes Forecast for Rigel Pharmaceuticals' Fostamatinib Disodium
...ssive efficacy, the spleen tyrosine kinase (Syk) inhibitor fostamatinib disodium will likely precede TNF-alpha inhibitors such as Amgen/Wyeth/Takeda's enbrel
and Abbott/Eisai's Humira in the treatment cascade for rheumatoid arthritis. Phase II data shows that fostamatinib disodium's efficacy is comparable t...
Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor (TNF) Blockers
...D WYETH STATEMENT:
Amgen and Wyeth believe that enbrel
continues to offer a favorable benefit-risk relati... Prescribing Information, and Medication Guide for enbrel
as described in the FDA communication which can be...t labeling to both physicians and patients.
was first approved for JIA in the U.S. in 1999. I...
Certain Arthritis, Crohn's Drugs May Raise Kids' Cancer Risk: FDA
...blockers, work by interrupting a protein that causes inflammation and damage to bones, cartilage and other tissue. They include Remicade (infliximab), enbrel
(etanercept), Humira (adalimumab), Cimzia (certolizumab pegol) and Simponi (golimumab).
"FDA announced that it has completed its analysis of TNF b...
Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29
...ease in the average net sales price partially offset by a decrease in units sold due to share declines as a result of increased competitive activity. enbrel
continues to maintain a leading position in both the rheumatology and dermatology segments.
Worldwide sales of Sensipar((R)) (cinacalcet) incre...
Wyeth Reports Earnings Results for the 2009 Second Quarter and First Half and Raises Full Year 2009 Guidance
...rength of our biotechnology and vaccine franchises enbrel
and Prevnar and our Nutritionals products, all of ...s key pharmaceutical franchises PREVNAR ((R)),( ) enbrel
((R)) (outside the U.S. and Canada) and Nutritiona...TORISEL ((R)) and the Hemophilia family and higher enbrel
alliance revenue. These increases were partially ...
Brazil's Rheumatoid Arthritis Drug Market Will Grow $115 Million by 2013
...results of Brazilian rheumatologists show regional differences in their preferences for agents within key drug classes for rheumatoid arthritis. While enbrel
emerges as the patient share leader among biologics in Rio de Janeiro, rheumatologists from Sao Paulo and Belo Horizonte prefer Humira and Remicade, r...
Enbrel in Medical Technology
Current and Emerging Drugs Have No Advantage Over Enbrel in Inhibiting/Slowing the Progression of Rheumatoid Arthritis
Although Some Emerging Therapies Hold Promise, Enbrel
Will Remain the Clinical Gold Standard Through 2016, According to a New Report from Decision Resources
WALTHAM, Mass., April 7, 2008 /PRNewswire/ -- Decision Resources, one
of the world's leading research and adv...
CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients
...mission, following the Committee's recommendation, enbrel
will become the
first biologic treatment indicated... for severe psoriasis in children and
is currently approved in the European Union for th...s from the study showed that patients treated
experienced a significant improvement of their pla...
Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
... established animal model of
rheumatoid arthritis. enbrel
is a leading treatment for people with
rheumatoid ...ignificant and uniform
disease state, therapy with enbrel
or CEL-2000 was initiated and continued
for 28 days. CEL-2000 was administered only twice and enbrel
administered either every day for the first 14...
Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
...t Amgen and Wyeth
Pharmaceuticals, co-marketers of enbrel
(R) (etanercept), will be the
national presenting ...Wyeth Pharmaceuticals, a division of Wyeth, market enbrel
North America. Wyeth markets enbrel
outside of North America. Immunex
Corporation, a w...
Positive Clinical Data on CC-10004 Confirms Potential as Novel Oral
Approach to Treating Inflammatory Diseases
Chief and Chair, Department of Dermatology of Tufts-New England
Medical Center. "The PASI-90 response of 14% for CC-10004 is
comparable to enbrel
dosed at 25 mg twice weekly."
Based on these results, Celgene is accelerating clinical and
regulatory strategies for CC-10004 in psoriasis, psoriati...
Enbrel Safety Data for up to Eight Years in Patients with Juvenile
Rheumatoid Arthritis Being Presented at EULAR
entered their eighth year of continuous enbrel
experienced a similar safety profile... in a double-blind,
randomized controlled trial of enbrel
(n=69) were eligible to
enroll in this multicenter...ctions
and medically important infections.
Enbrel in Biological Technology
Raptiva Withdrawal Offers Upside for Enbrel and Humira According to Latest BioTrends Survey of U.S. Dermatologists
EXTON, Pa., May 28 /PRNewswire/ -- BioTrends Research Group today released its syndicated report TreatmentTrends (R) : Psoriasis , the fourth annual survey of U.S. Dermatologists (n=150). The report, based on results of an on-line survey fielded in April, highlights shifting trends in th...
Latest BioTrends Research Reports to Assess the Impact of the Withdrawal of Raptiva (efalizumab) on the Psoriasis Market
...a had steadily declined since 2006 and only 44% of the dermatologists surveyed were using the product in their practices in April 2008. Amgen/Wyeth's enbrel
and Abbott's Humira, the most frequently prescribed biologics in psoriasis, were rated significantly higher than Raptiva on nearly all of the most imp...
Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
...mand due to increases in average net sales price. enbrel
sales growth in the fourth quarter and full year 2...ontinued in both rheumatology and dermatology, and enbrel
continues to maintain a leading position in both segments. For the full year, enbrel
sales were also favorably impacted by wholesaler i...
Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
...ases in both average
net sales price and patients. enbrel
sales growth in the third quarter was
affected by ...ontinued in both
rheumatology and dermatology, and enbrel
continues to maintain a leading
position in both s...ion to accelerate the closure of one of our enbrel
commercial bulk production operations in co...
Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months
...ceuticals Division Led by Solid Growth of enbrel
+32%, Nutritionals +18% and Prevnar +13%
-... 717 13% 2,113 12% enbrel
Outside U.S. and Canada 697 32% ...tain of our principal products, including Prevnar, enbrel
Nutrition products) prove incorrect, our a...
CBDM.T, The Market and Business Intelligence Company Reviews The Biomanufacturing Market
...…) and 40% are produced in microbial cells (E.coli: Infergen, Ontak, enbrel
and yeast: Novolog, Twinrix Pediarix…). Microbial fermentation is us...h drugs sold in the US. The top 5 leading biotech drugs sold in the USA are enbrel
(Amgen, Wyeth), Aranesp (Amgen), Rituxan (Biogen Idec, Genentech, Roche), R...
Dermatologists Report Increased Use of Biologics in the Treatment of Psoriasis
...cross the board, certain physician
types, particularly those newer to practice, seem to be more aggressive in
their use of these agents. Amgen/Wyeth's enbrel
continues to hold its
position as market leader amongst the biologics, however, Abbott's Humira
has increased its share significantly in the past year...
Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report
...ed in this report: allopurinol; febuxostat
(Teijin/Ipsen/TAP); Puricase (pegloticase; Savient); Remicade (infliximab;
(etanercept; Wyeth/Amgen); Humira
(adalimumab; Abbott), Orencia (abatacept; Bristol-Myers Squibb); MabThera
(rituximab; Roche/Biogen/Genentech); metho...
VLST Corporation Announces Board and Executive Management Appointments
...rd and to be working again with
VLST cofounder, Dr. Craig Smith. We worked together at Immunex," said
Urdal. "Craig's seminal work in the discovery of enbrel
is the basis for
VLST's novel drug discovery platform."
Dr. Urdal has served as Dendreon's chief scientific officer since 1995.
Prior to joining Den...
Centocor/Janssen-Cilag's Ustekinumab Will Become the Gold Standard for Psoriasis By 2011
... and clinical data shows that ustekinumab has advantages over
on this attribute.
"Clinical data and thought leader opinion indicate that ustekinumab and
Abbott/Eisai's Humira outperform enbrel
on efficacy and delivery measures,"
said Irene Koulinska, analyst at Decisi...